The primary function of the Galveston National Laboratory Advanced Veterinary Services (GAVS) Core is to support the Galveston National Laboratory's (GNL) mission on Biodefense and Emerging Infectious Diseases. The core will provide research support services, as well as training to sustain a highly skilled cadre of personnel with expertise on the development of animal models, host-pathogen relationships, and for testing of vaccines and therapeutics against aerosol challenge. The facility is designed to offer maximum flexibility, and will incorporate BSL-2/3/4 laboratories, with supporting animal research laboratories, aerobiology suites, a vivarium for small animals and non-human primates, necropsy room, and associated support spaces. However, we recognize the need to supplement or replace studies involving animals with alternative, scientifically valid approaches wherever possible, and to maximize the information gained from such studies. Our decision to establish and utilize a highly efficient skilled veterinary core facility was therefore based to a large extent on our efforts to limit the number and variety of animal species. Technologies including surgically implanted telemetric devices, laproscopic, endoscopic, and ultrasound guided tissue biopsies will be used to provide real time data with minimally invasive techniques. The core will be readily accessible and specifically designed, equipped, managed and operated to serve as a highly efficient national resource for the NIAID's Biodefense Network and other federally and non-federally supported biodefense and emerging infections research programs. In the event of a national bioterrorism or emerging disease emergency, the proposed GAVS Core will offer surge laboratory capacity, trained laboratory personnel, diagnostic, and expert consultation to local, regional, state, and national entities involved in first response and biological incident management. The GAVS Core Director, in consultation with the GNL administrative core will direct and prioritize all activities with the aim of assisting NIAID-funded biodefense investigators from institutions lacking appropriate biocontainment facilities, technology, and/or training.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
National Biocontainment Laboratory Operation Cooperative Agreement (UC7)
Project #
5UC7AI070083-04
Application #
7903129
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
4
Fiscal Year
2009
Total Cost
$2,142,856
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Type
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Andersson, Jourdan A; Sha, Jian; Kirtley, Michelle L et al. (2018) Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics. Antimicrob Agents Chemother 62:
Beasley, David W C; Brasel, Trevor L; Comer, Jason E (2016) First vaccine approval under the FDA Animal Rule. NPJ Vaccines 1:16013
Sha, Jian; Kirtley, Michelle L; Klages, Curtis et al. (2016) A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates. Clin Vaccine Immunol 23:586-600
Fitts, Eric C; Andersson, Jourdan A; Kirtley, Michelle L et al. (2016) New Insights into Autoinducer-2 Signaling as a Virulence Regulator in a Mouse Model of Pneumonic Plague. mSphere 1:
Tiner, Bethany L; Sha, Jian; Cong, Yingzi et al. (2016) Immunisation of two rodent species with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague. NPJ Vaccines 1:16020
Andersson, Jourdan A; Fitts, Eric C; Kirtley, Michelle L et al. (2016) New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria. Antimicrob Agents Chemother 60:3717-29
Tiner, Bethany L; Sha, Jian; Kirtley, Michelle L et al. (2015) Combinational deletion of three membrane protein-encoding genes highly attenuates yersinia pestis while retaining immunogenicity in a mouse model of pneumonic plague. Infect Immun 83:1318-38
Rasmussen, Lynn; Tigabu, Bersabeh; White, E Lucile et al. (2015) Adapting high-throughput screening methods and assays for biocontainment laboratories. Assay Drug Dev Technol 13:44-54
Boisen, Matthew L; Schieffelin, John S; Goba, Augustine et al. (2015) Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. Viral Immunol 28:19-31
Falzaran, D; Bente, D A (2015) Animal models for viral haemorrhagic fever. Clin Microbiol Infect :

Showing the most recent 10 out of 43 publications